15 research outputs found
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
Get PDFHypersensitivity reactions (HSRs) to paclitaxel are frequently encountered in patients receiving this antitumour drug. Administration of histamine H1- and H2-receptor antagonists and corticosteroids has been shown to reduce significantly the risk of developing an HSR in patients receiving taxanes. In this case report, we describe the fatal outcome of an HSR in a patient receiving paclitaxel despite short-course premedication. The level of evidence supporting the short-course i.v. premedication schedule is challenged, as it is not compatible with the pharmacokinetic properties of dexamethasone
Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Full text linkAncistroheynine A, the first 7,8'-coupled naphtylisoquinoline alkaloid from Ancistrocladus heyneanus
No full text
Peripheral T-cell non-Hodgkin's lymphomas of low malignancy: prospective study of 25 patients with pleomorphic small cell lymphoma, lymphoepitheloid cell (Lennert's) lymphoma and T-zone lymphoma
No full textTapering and Discontinuation of Glucocorticoid Prophylaxis during Prolonged Weekly to Biweekly Paclitaxel Administration
No full text
